Martina A. Sersch, M.D., Ph.D., has been appointed chief medical officer, Mustang Bio, Inc. Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies.

Dr. Sersch has more than 17 years of experience in early- and late-stage clinical development in academia and industry, with specialty training in oncology, infectious and tropical diseases. Prior to joining Mustang, Dr. Sersch served as executive director at Amgen, where she successfully led supplemental Biologics License Application filings in the area of hematology, as well as indication strategies for early- and late-stage compounds in hematology. Prior to Amgen, Dr. Sersch held positions of increasing responsibility in oncology drug development, including novel immuno-oncology drugs at IRAD Oncology, Genentech, Roche and Pfizer.

Manuel Litchman, M.D., president and chief executive officer of Mustang, said, “We are delighted to welcome Martina to the Mustang leadership team. Her extensive global immuno-oncology drug development expertise and vast array of experience in bringing innovative oncology products to market will help guide Mustang’s clinical development efforts and regulatory strategies in an exciting time of growth for the company.”

Dr. Sersch said, “I am thrilled to join Mustang to help advance the development of its CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as its lentiviral gene therapy for XSCID. I look forward to working with the Mustang team as we strive to deliver promising new treatment options for patients and their families in areas of unmet medical need.”